ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces today that it has completed the enrolment of the second Phase III trial evaluating microplasmin for the non-surgical treatment of eye disease. The trial TG-MV-007, which recruited patients both in [...]

ThromboGenics NV (Euronext Brussels: THR) and co-development partner BioInvent International (OMXS: BINV) announce that they have completed recruitment of their Phase II trial of TB-402 ahead of schedule. TB-402 is a novel, long acting anticoagulant that is being developed for the prevention of deep vein thrombosis (DVT) following orthopaedic surgery. The results of this study, [...]

Post-operative anaemia is a recognised complication of total hip replacement and can increase the length of hospital stay, delay rehabilitation and is poorly tolerated by patients with vascular disease. Current practice sees homologous blood transfusion commonly used to correct blood loss, however, it is associated with risk of infection, viral transmission, fluid overload and high [...]

Hip resurfacing can be a good alternative to total hip replacement (THR) in young adults because it conserves bone and it has acceptable short- to medium-term results. However, there have been concerns about fractures of the femoral neck with this procedure, partly due to notching and varus alignment during implantation.

Research published on 1st March 2009 investigates whether ’simultaneous bilateral sequential total hip replacement (THR) would increase the rate of mortality and complications compared with unilateral THR’, for both low and high risk patients.